Pathology: breast cancer - adjuvant; es-BC - HER2 positive - (neo)adjuvant (NA); la/mBC - HER2 positive - 1st Line (L1); la/mBC - HER2 positive - 2nd Line (L2); la/mBC - HR-positive - 1st line (L1);
| breast cancer - adjuvant | es-BC - HER2 positive - (neo)adjuvant (NA) | la/mBC - HER2 positive - 1st Line (L1) | la/mBC - HER2 positive - 2nd Line (L2) | la/mBC - HR-positive - 1st line (L1) | |||||||||||||
| BCIRG-006 (TCH vs AC-T), 2011 | BCIRG-006 (AC-TH vs TCH), 2011 | BCIRG-006 (AC-TH vs AC-T), 2011 | ExteNET, 2016 | APHINITY, 2017 | GeparQuinto, 2012 | PERTAIN, 2018 | PUFFIN, 2020 | CLEOPATRA, 2012 | SYSUCC-002, 2022 | ExteNET, 2016 | NALA, 2020 | NALA (brain metastases), 2020 | HER2CLIMB (patients with brain metastases), 2020 | HER2CLIMB, 2020 | SYSUCC-002, 2022 | ||
| trastuzumab plus endocrine therapy | 2 | T1 | T1 | ||||||||||||||
| neratinib plus capecitabine | 2 | T1 | T1 | ||||||||||||||
| tucatinib plus trastuzumab plus capecitabine | 2 | T1 | T1 | ||||||||||||||
| pertuzumab plus trastuzumab | 2 | T1 | T1 | ||||||||||||||
| neratinib | 2 | T1 | T1 | ||||||||||||||
| pertuzumab plus trastuzumab plus docetaxel | 2 | T1 | T1 | ||||||||||||||
| doxorubicin plus cyclophosphamide followed by docetaxel plus trastuzumab | 2 | T1 | T1 | ||||||||||||||
| trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel | 1 | T1 | |||||||||||||||
| docetaxel plus carboplatin with trastuzumab followed by trastuzumab | 1 | T1 | T0 | ||||||||||||||
| trastuzumab plus chemotherapy | 0 | T0 | T0 | ||||||||||||||
| lapatinib plus capecitabine | 0 | T0 | T0 | ||||||||||||||
| trastuzumab plus capecitabine | 0 | T0 | T0 | ||||||||||||||
| trastuzumab | 0 | T0 | T0 | ||||||||||||||
| placebo | 0 | T0 | T0 | ||||||||||||||
| trastuzumab plus docetaxel | 0 | T0 | T0 | ||||||||||||||
| lapatinib plus epirubicin and cyclophosphamide followed by docetaxel | 0 | T0 | |||||||||||||||
| doxorubicin plus cyclophosphamide followed by docetaxel | 0 | T0 | T0 | ||||||||||||||